{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:22:02Z","timestamp":1787829722807,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,29]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Cancer therapy-induced thrombocytopenia (CTIT) is a common complication in patients with solid tumors during their cancer treatment. The sole therapeutic agents approved for this indication are recombinant human interleukin-11 (rhIL-11) or recombinant human thrombopoietin (rhTPO). Romiplostim-N01 is a novel thrombopoietic agent launched in China in 2024, which has demonstrated preliminary therapeutic efficacy in the management of CTIT. This retrospective study compared romiplostim-N01 with rhIL-11 or rhTPO for CTIT management. Ninety-two matched consecutive patients with grade \u22652 CTIT (platelet [PLT] count\u2005&lt;\u200575\u2005\u00d7\u200510\n                      <jats:sup>9<\/jats:sup>\n                      \/L) were grouped into either the romiplostim-N01 group or the rhIL-11\/rhTPO group. The primary endpoint was the proportion of treatment-marked responders, defined as patients who reached a PLT count of \u2265100\u2005\u00d7\u200510\n                      <jats:sup>9<\/jats:sup>\n                      \/L and at least 30\u2005\u00d7\u200510\n                      <jats:sup>9<\/jats:sup>\n                      \/L higher than the pretreatment baseline within 7 days of treatment. Propensity score matching and a multivariate logistic regression model were used to estimate the treatment effects of the 2 drugs on CTIT. The 7-day marked response rate was significantly higher in the romiplostim-N01 group compared with the control group (58.7% vs 28.3%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.05), whereas the 14-day overall response rate was comparable between the 2 groups (89.1% vs 89.1%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&gt;\u2005.05). The median duration of chemotherapy delay was significantly shorter in the romiplostim-N01 group compared with the rhIL-11\/rhTPO group (5.5 vs 9.5 days,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001). Multivariate regression analysis confirmed that romiplostim-N01 was independently associated with an elevation in PLT count. These findings position romiplostim-N01 as a favorable alternative to rhIL-11 or rhTPO in CTIT, given its enhanced early PLT response and reduced risk of chemotherapy disruption.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048855","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:06:17Z","timestamp":1780074377000},"page":"e48855","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Romiplostim-N01 for cancer therapy-induced thrombocytopenia: A propensity score-matched cohort study"],"prefix":"10.1097","volume":"105","author":[{"given":"Ting","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Clinical Research Center for Cancer, Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiman","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Clinical Research Center for Cancer, Nanchang, Jiangxi, China"},{"name":"Jiangxi Medical College, Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfeng","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Clinical Research Center for Cancer, Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jian","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Clinical Research Center for Cancer, Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Clinical Research Center for Cancer, Nanchang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6226-5299","authenticated-orcid":false,"given":"Yaqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Clinical Research Center for Cancer, Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20260827","doi-asserted-by":"crossref","first-page":"e1609","DOI":"10.1002\/onco.13822","article-title":"Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis.","volume":"26","author":"Nielson","year":"2021","journal-title":"Oncologist"},{"key":"R3-20260827","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO.2001.19.4.1137","article-title":"Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia.","volume":"19","author":"Elting","year":"2001","journal-title":"J Clin Oncol"},{"key":"R4-20260827","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/hematology.2022000374","article-title":"Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem.","volume":"2022","author":"Al-Samkari","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R5-20260827","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3324\/haematol.2021.279512","article-title":"Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies.","volume":"107","author":"Kuter","year":"2022","journal-title":"Haematologica"},{"key":"R6-20260827","doi-asserted-by":"crossref","first-page":"101139","DOI":"10.1016\/j.blre.2023.101139","article-title":"Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists.","volume":"63","author":"Al-Samkari","year":"2024","journal-title":"Blood Rev"},{"key":"R7-20260827","doi-asserted-by":"crossref","first-page":"101222","DOI":"10.1016\/j.blre.2024.101222","article-title":"Immune thrombocytopenia: pathophysiology and impacts of romiplostim treatment.","volume":"67","author":"Semple","year":"2024","journal-title":"Blood Rev"},{"key":"R8-20260827","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia.","volume":"37","author":"Soff","year":"2019","journal-title":"J Clin Oncol"},{"key":"R9-20260827","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2478\/jtim-2023-0106","article-title":"Efficacy and safety of QL0911 in adult patients with chronic primary immune thrombocytopenia: a multicenter, randomized, double-blind, placebo-controlled, phase III trial.","volume":"11","author":"Zhou","year":"2023","journal-title":"J Transl Int Med"},{"key":"R10-20260827","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3324\/haematol.2020.251900","article-title":"A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies.","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"key":"R12-20260827","first-page":"519","article-title":"Expert consensus on the clinical application of romiplostim (2024 Edition).","volume":"33","year":"2024","journal-title":"J Leuk Lymphoma"},{"key":"R13-20260827","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2147\/DDDT.S299591","article-title":"A review of romiplostim mechanism of action and clinical applicability.","volume":"15","author":"Bussel","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"R14-20260827","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00277-010-0908-2","article-title":"Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects.","volume":"89","author":"Jawa","year":"2010","journal-title":"Ann Hematol"},{"key":"R15-20260827","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-016-0382-7","article-title":"Development of romiplostim for treatment of primary immune thrombocytopenia from a pharmacokinetic and pharmacodynamic perspective.","volume":"55","author":"Yang","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"R16-20260827","doi-asserted-by":"crossref","first-page":"e7429","DOI":"10.1002\/cam4.7429","article-title":"Romiplostim in chemotherapy-induced thrombocytopenia: a review of the literature.","volume":"13","author":"Soff","year":"2024","journal-title":"Cancer Med"},{"key":"R17-20260827","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.3324\/haematol.2017.180166","article-title":"The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors.","volume":"103","author":"Al-Samkari","year":"2018","journal-title":"Haematologica"},{"key":"R18-20260827","doi-asserted-by":"crossref","first-page":"e12701","DOI":"10.1002\/rth2.12701","article-title":"Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use.","volume":"6","author":"Wilkins","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"R19-20260827","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/bjh.17387","article-title":"Immune thrombocytopenia after immune checkpoint inhibitor therapy.","volume":"193","author":"Amanam","year":"2021","journal-title":"Br J Haematol"},{"key":"R20-20260827","doi-asserted-by":"crossref","first-page":"109015","DOI":"10.1016\/j.intimp.2022.109015","article-title":"Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: a real-world study of the FDA adverse event reporting system.","volume":"110","author":"Moore","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"R21-20260827","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/10781552211073883","article-title":"Thrombotic thrombocytopenic purpura associated with pembrolizumab.","volume":"28","author":"Nelson","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"R22-20260827","first-page":"2579","article-title":"Consensus on the clinical diagnosis, treatment and prevention of cancer treatment-induced thrombocytopenia in China (2023 edition) [in Chinese].","volume":"103","year":"2023","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"R23-20260827","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors.","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur J Cancer"},{"key":"R24-20260827","doi-asserted-by":"crossref","first-page":"1407894","DOI":"10.3389\/fphar.2024.1407894","article-title":"Association of thrombocytopenia with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis based on the data from FDA adverse event reporting system database.","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol"},{"key":"R25-20260827","first-page":"1441","article-title":"Analysis of 972 spontaneous reports of adverse drug reactions induced by angiogenesis inhibitors.","volume":"37","author":"Yan","year":"2021","journal-title":"Chin J Clin Pharmacol"},{"key":"R26-20260827","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer.","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R27-20260827","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC.","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R28-20260827","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41392-025-02337-1","article-title":"Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis.","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct Target Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:00:51Z","timestamp":1787828451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":26,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048855","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"2025-12-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}